Purple Biotech Is Building Next-Generation Cancer Immunotherapy in a Space Where Deals Are Measured in Billions (NASDAQ: PPBT)
Purple Biotech’s CAPTN-3 platform uses conditionally activated tri-specific antibody technology, part of a broader class of multispecific antibodies that has commanded $700 million+ upfront payments and multi-billion-dollar transactions across the pharmaceutical industry – yet the company trades at a single-digit-million valuation (NASDAQ: PPBT). For

